Ann: Paradigm Receives $7.36m R&D Tax Incentive Refund, page-40

I think most seem to be hoping for a
share price miracle with MPS results. Whether
they are good or bad, I believe it is all just a
sideshow to the main event. Too much time
money and preoccupation has been spent on
MPS. IMO we are bound for disappointment
if we expect substantial upfront payments with
an MPS partnership deal; and I hope I am
wrong, but I believe we will rue the day that
2mg/twice weekly was not included in the
002 OA dosing study. It seems to be an
almighty waste of resources to use half of the
002 trial recipients just for the dosing study
and 2x2 was not included. Time will tell.